District Court Rules in Favor of Heron in CINVANTI Patent Lawsuit

December 4, 2024

DENVER, Colo., Dec 04, 2024 (247marketnews.com)- The U.S. District Court for the District of Delaware ruled in favor of Heron Therapeutics (NASDAQ: HRTX) in its patent litigation against Fresenius Kabi USA with respect to CINVANTI (aprepitant) injectable emulsion. The court determined that Heron’s U.S. Patents, 9,561,229 and 9,974,794, are valid and would be infringed by Fresenius’ proposed generic product.

Heron will now seek a Court order barring Fresenius from launching its generic CINVANTI until after the patents expire in 2035.

Craig Collard, Heron’s CEO, stated, “We are pleased with this anticipated result of the proceeding and will continue to vigorously defend the CINVANT patent estate in the future.

“The team at Heron takes great pride in the result of our successful history of developing injectable products, which is demonstrated by the strength of our intellectual property and the performance of our innovative drugs like CINVANTI® in serving patients with serious unmet needs.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (HRTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.